Relay Therapeutics is projected to report Q3 2026 revenue of $1.59 million and a consensus loss per share of $0.40, while its current $18.35 price remains 50% below the $27.58 average analyst target.
Investors are primarily focused on clinical updates regarding the Phase 3 ReDiscover-2 trial for RLY-2608 (zovegalisib), the company’s lead candidate for PI3Kα-mutated breast cancer. The report follows the recent FDA Breakthrough Therapy designation for the treatment, which has heightened expectations for upcoming pivotal data readouts. Management’s ability to control quarterly net losses and maintain a cash runway extending into late 2027 remains a critical metric for long-term spending discipline.